Abbott Laboratories $ABT Stock Sold by Wealth Science Advisors LLC

Wealth Science Advisors LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 71.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,363 shares of the healthcare product maker’s stock after selling 5,982 shares during the quarter. Wealth Science Advisors LLC’s holdings in Abbott Laboratories were worth $234,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ABT. BlackRock Inc. grew its stake in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the period. State Street Corp raised its position in shares of Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. J. Stern & Co. LLP lifted its holdings in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Abbott Laboratories by 0.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock valued at $2,241,076,000 after purchasing an additional 118,014 shares during the period. Finally, Bank of America Corp DE bought a new stake in Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABT shares. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Wells Fargo & Company raised their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Barclays began coverage on Abbott Laboratories in a report on Wednesday. They set an “overweight” rating and a $120.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.88.

Abbott Laboratories Stock Up 1.2%

ABT opened at $99.71 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company’s 50-day moving average is $106.25 and its 200 day moving average is $98.35. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $134.50. The firm has a market capitalization of $172.53 billion, a P/E ratio of 32.27, a PEG ratio of 1.83 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.